EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study

Hao-Chih Chang iD, Yun-Yu Chen iD, Tzu-Ting Kuo, Yenn-Jiang Lin iD, Kuo-Liong Chien iD, Hung-Yu Chang iD, Chung-Lieh Hung iD, Fa-Po Chung iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.032397 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Hao-Chih Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Taipei Veterans General Hospital Taoyuan Branch Taoyuan Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Metformin, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study investigated whether initial SGLT2 (sodium‐glucose cotransporter 2) inhibitor‐based treatment is superior to metformin‐based regimens as a primary prevention strategy among low‐risk patients with diabetes. Methods and Results In this nationwide cohort study, a total of 38 496 patients with diabetes with low cardiovascular risk were identified (age 62.0±11.6 years, men 50%) from January 1 to December 31, 2016. Patients receiving SGLT2 inhibitors‐based and metformin‐based regimens were 1:2 matched by propensity score. Study outcomes included all‐cause mortality, cardiovascular death, hospitalization for heart failure, stroke, and progression to end‐stage renal disease. Compared with 1928 patients receiving metformin‐based regimens, 964 patients receiving SGLT2 inhibitor‐based regimens had similar all‐cause mortality (hazard ratio [HR], 0.75 [95% CI, 0.51–1.12]), cardiovascular death (HR, 0.69 [95% CI, 0.25–1.89]), hospitalization for heart failure (HR, 1.06 [95% CI, 0.59–1.92]), stroke (HR, 0.78 [95% CI, 0.48–1.27]), and progression to end‐stage renal disease (HR, 0.88 [95% CI, 0.32–2.39]). However, SGLT2 inhibitors were associated with a lower risk of all‐cause mortality (HR, 0.47 [95% CI, 0.23–0.99]; P for interaction=0.008) and progression to end‐stage renal disease (HR, 0.22 [95% CI, 0.06–0.82]; P for interaction=0.04) in patients under the age of 65.

Conclusions

In comparison to metformin‐based regimens, SGLT2 inhibitor‐based regimens showed a similar risk of all‐cause mortality and adverse cardiorenal events. SGLT2 inhibitors might be considered as first‐line therapy in select low‐risk patients, for example, younger patients with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsMetforminDiabetes Mellitus, Type 2Cardiovascular DiseasesHeart FailureKidney Failure, ChronicStrokeMaleHumansMiddle AgedAgedCohort StudiesRisk FactorsTreatment OutcomeHeart Disease Risk FactorsGlucoseHypoglycemic Agents

Stichwörter der Autor:innen

low cardiovascular riskmetforminsodium‐glucose cotransporter 2 inhibitorstype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMetforminGlucoseHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Medicine Taipei Veterans General Hospital Taoyuan Branch Taoyuan Taiwan.
  • Cardiovascular Research Center, School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan.
  • Heart Rhythm Center, Division of Cardiology, Department of Medicine Taipei Veterans General Hospital Taipei Taiwan.
  • Department of Medical Research Taichung Veterans General Hospital Taichung Taiwan.
  • Institute of Epidemiology and Preventive Medicine, College of Public Health National Taiwan University Taipei Taiwan.
  • Department of Post Baccalaureate National Chung Hsing University Taichung Taiwan.

ORCID-Profile: Hao-Chih Chang, Yun-Yu Chen, Yenn-Jiang Lin, Kuo-Liong Chien, Hung-Yu Chang, Chung-Lieh Hung, Fa-Po Chung

Zitieren

APA

Chang, H. C., Chen, Y. Y., Kuo, T. T., Lin, Y. J., Chien, K. L., Chang, H. Y., Hung, C. L., & Chung, F. P. (2024). Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.032397

Vancouver

Chang HC, Chen YY, Kuo TT, Lin YJ, Chien KL, Chang HY, et al. Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.032397

BibTeX
@article{Chang2024,
  author = {Chang, Hao-Chih and Chen, Yun-Yu and Kuo, Tzu-Ting and Lin, Yenn-Jiang and Chien, Kuo-Liong and Chang, Hung-Yu and Hung, Chung-Lieh and Chung, Fa-Po},
  title = {Sodium Glucose Transporter 2 Inhibitors Versus Metformin on Cardiovascular and Renal Outcomes in Patients With Diabetes With Low Cardiovascular Risk: A Nationwide Cohort Study},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.032397}
}
Kostenlos starten →